Drug Trial Radar · NCT04238364
A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
Dec 27, 2019
Primary completion
Dec 16, 2021
Study completion Jan 10, 2022
Sponsor
- Lead sponsor
- Elixiron Immunotherapeutics Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Jan 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This was a first-in-human study to determine the safety, tolerability, and pharmacokinetics of EI1071 after single and multiple doses in healthy volunteers.
Conditions
- Healthy Volunteers
Interventions
EI-1071Drug
EI-1071 Tablet(s)
PlaceboDrug
Matching Placebo Tablet(s)
Primary outcomes
What the sponsor says the trial is designed to measure.
- After single ascending doses, number of subjects with treatment-emergent adverse events (TEAEs) after dosing with EI-1071Time frame: Up to 7 days
- After multiple ascending doses, number of subjects with TEAEs after dosing with EI-1071Time frame: Up to 21 days
- After multiple ascending doses, number of subjects with adverse events (AEs) leading to discontinuation in the EI-1071 cohorts.Time frame: Up to 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Parexel Early Phase Clinical Unit
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.